Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

5.250 -0.240 (-4.37%)
Streaming Delayed Price Updated: 2:16 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,518
Open 5.340
Bid (Size) 5.170 (200)
Ask (Size) 5.350 (300)
Prev. Close 5.490
Today's Range 5.170 - 6.000
52wk Range 3.800 - 14.99
Shares Outstanding 17,025,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
From Avacta Group PLC
Via GlobeNewswire
News headline image
Leishen Energy Holding Co., Ltd. Announced Fiscal Year 2025 Financial Results Highlighting Strong Operating Cash Flow and Low Financial Leverage
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire

Performance

YTD
+23.0%
+23.0%
1 Month
+13.2%
+13.2%
3 Month
+1.7%
+1.7%
6 Month
-2.1%
-2.1%
1 Year
-1.7%
-1.7%

More News

Read More
News headline image
Corero Network Security to Present at the AI & Technology Virtual Investor Conference February 19th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Avacta appoints Francis Wilson as Chief Scientific Officer
From Avacta Group PLC
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2025 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Interim Results for the six months ended 31 October 2025
From Scancell Holdings Plc
Via GlobeNewswire
News headline image
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
From Scancell Holdings Plc
Via GlobeNewswire
News headline image
Leishen Energy Holding Co., Ltd. Announces Receipt of Nasdaq Notice Regarding Annual Meeting Requirement
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
News headline image
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
Avacta Announces Year-end Trading Update
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Caledonia Mining Corporation Plc: Director/PDMR Shareholding Notification
From Caledonia Mining Corporation Plc
Via GlobeNewswire
News headline image
Caledonia Mining Corporation Plc: Zimbabwe government amends proposed changes to the royalty and tax regimes
From Caledonia Mining Corporation Plc
Via GlobeNewswire
News headline image
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
From AVACTA GROUP PLC
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Caledonia Mining Corporation Plc: Utilisation of the block admission in respect of ATM Sales Agreement
From Caledonia Mining Corporation Plc
Via GlobeNewswire
News headline image
Caledonia Mining Corporation Plc: Notification of relevant change to significant shareholder
From Caledonia Mining Corporation Plc
Via GlobeNewswire
News headline image
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
From Scancell Holdings Plc
Via GlobeNewswire
News headline image
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares publicly traded?
Yes, Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is publicly traded.
What exchange does Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trade on?
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is LSE on the Nasdaq Stock Market
What is the current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 5.250
When was Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares last traded?
The last trade of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares was at 03/03/26 02:16 PM ET
What is the market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?
The market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 89.38M
How many shares of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares are outstanding?
Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares has 89M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.